PTAB Invalidates Humira Patent In Coherus Challenge
The PTAB’s decision in inter partes review is a victory for Coherus BioSciences Inc., a California biosimilars company that, according to published reports, has been looking to launch a copycat of Humira, the world’s best-selling pharmaceutical.
The patent covers a Humira dosing regimen to treat rheumatoid arthritis. Coherus argued it would have...
To view the full article, register now.